Year : 2014  |  Volume : 16  |  Issue : 5  |  Page : 666

Reappraisal of glucocorticoids in castrate-resistant prostate cancer

1 Department of Urology and Medicine, Tulane Medical School, Tulane, New Orleans, Louisiana, USA
2 Department of Urology, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Correspondence Address:
Oliver Sartor
Department of Urology and Medicine, Tulane Medical School, Tulane, New Orleans, Louisiana
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1008-682X.133314

Rights and Permissions

Recent reports and discussions of preclinical prostate cancer models have emphasized the possibility that enzalutamide resistance may be mediated by glucocorticoid receptors (GR). [1],[2] In both in vitroand xenograft animal studies, it is possible to show that the GR is up-regulated in prostate cancer cell lines and that dexamethasone reverses enzalutamide induced growth inhibition. In these model systems, GR agonists can induce a subset of androgen receptor target genes including prostate-specific antigen. These investigators also report a correlation between GR expression in patient-derived prostate cancer specimens and clinical response to enzalutamide. The authors discuss the possibility that these findings have important clinical relevance. We note that the current clinical evidence for GR mediating drug resistance or disease progression in patients with castrate-resistant prostate cancer (CRPC) is very limited at best.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded442    
    Comments [Add]    
    Cited by others 4    

Recommend this journal